Orakl Oncology, a Paris, France-based precision oncology startup, raised €3M in funding.
The round was led by Speedinvest with additional investment from HCVC and Verve Ventures.
Orakl Oncology is combining cell biology, engineering and machine learning to build unique tumor avatars for each individual cancer patient that can mimic real-life responses to drugs. The company’s collection of avatars captures the complexity and heterogeneity of cancer at the population scale, helping pharma and biotech companies to identify new therapeutic targets or predictive biomarkers and increase clinical trial success rates.
Launched in 2023 as a spin-out from the Gustave Roussy Institute by co-founders Fanny Jaulin, Diane-Laure Pagès and Gustave Ronteix, Orakl Oncology is targeting the global oncology market, with an initial focus on colorectal and pancreatic cancers – the second leading-cause of cancer deaths worldwide.
The company intends to use the funds to launch its wet and dry lab capabilities and to hire several key team members, including a Senior Oncology Scientist, Organoid Scientists, a Head of Lab, an Automation Engineer and an AI Research Scientist. This will enable Orakl Oncology to execute its first contracts with pharma and biotech partners.
FinSMEs
04/10/2023